Analyst Price Targets — PTHS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 12:52 am | — | Roth Capital | $55.00 | $23.00 | TheFly | Pelthos Therapeutics price target lowered to $55 from $57 at Roth Capital |
| January 26, 2026 1:22 pm | — | Oppenheimer | $60.00 | $24.75 | TheFly | Pelthos Therapeutics price target raised to $60 from $57 at Oppenheimer |
| December 3, 2025 1:13 pm | — | Lake Street | $50.00 | $27.38 | TheFly | Pelthos Therapeutics initiated with a Buy at Lake Street |
| December 3, 2025 11:11 am | — | H.C. Wainwright | $60.00 | $25.14 | TheFly | Pelthos Therapeutics initiated with a Buy at H.C. Wainwright |
| November 25, 2025 9:29 am | — | Roth Capital | $57.00 | $27.53 | TheFly | Pelthos Therapeutics initiated with a Buy at Roth Capital |
| September 2, 2025 10:18 am | — | UBS | $50.00 | $22.46 | TheFly | Pelthos Therapeutics initiated with an Outperform at Oppenheimer |
Latest News for PTHS
Pre-Market Stock Futures: The futures are trading lower as we get set to conclude one of the zaniest trading weeks the stock market has seen in a long time. Despite crushing analysts' earnings estimates and giving forward guidance above consensus, Nvidia Corp. (NASDAQ: NVDA) initially opened higher amid a rush of retail buying. Still, the... Here Are Friday's Top Wall Street Analyst Research Calls: Block, Costco,…
FARMINGTON, Conn.--(BUSINESS WIRE)--Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos Therapeutics Inc. (NYSE American: PTHS) (“Pelthos”), with an initial funding of $30 million, and up to $20 million to support future growth. Pelthos is a publicly traded biopharmaceutical…
The minimally dilutive funding will accelerate Pelthos' highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum, two newly acquired FDA approved cutaneous infectious disease products and for working capital and general corporate purposes The minimally dilutive funding will accelerate Pelthos' highly successful…
DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has acquired Xeglyze® (abametapir) from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 million.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PTHS.
U.S. House Trading
No House trades found for PTHS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.